Bifidobacterium animalis subsp. lactis BL-04 is the third probiotic strain in the ProDentim formula and the one most readers know least about. Unlike the two lactobacilli, which target gum tissue directly, BL-04 was originally developed and studied for its effects on respiratory and immune function. Including it in an oral health supplement is a deliberate choice that reflects how the upper airway and oral cavity share a continuous mucosal surface. This article unpacks what BL-04 does, what the trials show, and why it earns a spot in the formula.
What BL-04 Is
Bifidobacterium animalis subsp. lactis is a Gram-positive, anaerobic, rod-shaped probiotic species widely used in dairy fermentation and dietary supplements. The BL-04 designation refers to a specific strain owned and characterized by Danisco/DuPont. It was deposited in the Belgian Coordinated Collection of Microorganisms in the late 1990s and has been the subject of more than two dozen human clinical trials since then. The strain is notable for surviving stomach acid and bile better than many bifidobacteria, which historically limited their viability in supplements.
Why an Immune-Focused Probiotic in an Oral Product
The mouth, throat, nasopharynx, and sinuses are connected by continuous mucous membranes, share lymphoid tissue (the Waldeyer's ring of tonsillar tissue), and host overlapping microbial communities. Oral pathogens regularly seed the throat; respiratory pathogens regularly land in the mouth. When you support the immune defenses of one part of this connected system, you tend to support the others.
BL-04 specifically has been shown to modulate certain immune markers (most notably secretory IgA and natural killer cell activity) and to reduce the incidence of upper respiratory tract infections in active adults. The ProDentim formula folds this into a broader oral health story: cleaner mouth, more competition for opportunistic pathogens, and a small immune nudge.
The Headline Trials
The most cited BL-04 trial is a 5-month double-blind randomized controlled study in physically active adults, published in Clinical Nutrition in 2014 by West and colleagues at Griffith University. The study found that BL-04 supplementation was associated with a meaningful delay in the onset of upper respiratory tract infection compared to placebo. The mechanism appears to involve enhanced mucosal immune responses rather than direct antimicrobial action.
A more recent in vitro study (PMID 38665561) reported antiviral activity of BL-04 against several respiratory viruses in cultured epithelial cells, providing a plausible mechanism for the clinical findings. A separate experimental rhinovirus challenge study (Turner et al. 2017) examined whether BL-04 could reduce symptom severity following deliberate viral inoculation; results were modest but pointed in the right direction.
How BL-04 Interacts with the Oral Cavity
BL-04 is not a classical periodontal-focused probiotic. It does not have the same documented anti-gingivitis effects as L. reuteri or the same anti-cariogenic effects as some L. paracasei strains. What it appears to do in the mouth-throat axis is help maintain a balanced anaerobic population in the posterior tongue and tonsillar crypts. This matters because the tongue's posterior dorsum is the single largest reservoir of bacteria in the oral cavity, including most of the volatile sulfur-compound producers responsible for chronic bad breath. We discuss bad breath in detail in our bad breath blog post.
Why Strain ID Matters Here Too
As with L. paracasei, the species name B. animalis subsp. lactis covers many strains, and their clinical profiles diverge. BB-12, HN019, Bi-07, and BL-04 are all subsp. lactis strains, all sold commercially, and each has its own published research base. Studies on BB-12 cannot be assumed to apply to BL-04 even though they share a subspecies designation. ProDentim's label specifies BL-04, which is the appropriate practice and lets researchers and clinicians match the product to the published evidence.
Dose and Delivery
Published BL-04 trials have generally used daily doses in the range of 1 to 4 billion CFU, taken once daily for periods of weeks to months. ProDentim delivers its blended probiotic load (3.5 billion total CFU across three strains) in a single soft chewable tablet. The chewable format gives BL-04 contact time with the tongue and posterior oropharynx that a capsule swallowed whole would skip.
Safety Profile
Bifidobacterium species have an extensive safety record, including in infants and elderly populations. BL-04 specifically has been administered in multiple trials without serious adverse events. The species is generally regarded as safe (GRAS) by the FDA when used in food. As with any probiotic, severely immunocompromised individuals should consult a physician before use; the risk of probiotic bacteremia is exceedingly low but not zero in that specific population.
What BL-04 Will Not Do
It is worth being explicit. BL-04 is not a cold cure, not an anti-flu agent, and not a treatment for any disease. The trial evidence describes incidence reduction and immune modulation in healthy or active adults; it does not justify claims of disease prevention. Its inclusion in ProDentim is best understood as a long-term immune-support adjunct that happens to live in the same mucosal neighborhood as the oral targets of the other ingredients.
The Synergy Argument
The three probiotic strains in the ProDentim formula work on different pieces of the same problem: L. paracasei on adhesion and competition with periodontal/cariogenic pathogens, L. reuteri on direct antimicrobial action through reuterin and on gingival inflammation, and BL-04 on immune support along the upper airway. The supporting nutrients (inulin as a prebiotic substrate, malic acid for saliva and stain, tricalcium phosphate for enamel, peppermint for breath) round out the formulation. Read the per-ingredient breakdown on our ingredients page.
Bottom Line on BL-04
BL-04 is a well-characterized, well-studied strain with credible evidence for immune support, particularly in the upper airway. Its inclusion in an oral probiotic blend is defensible and consistent with the modern understanding of the oral-respiratory mucosal axis. It is not the headline strain for gum health benefits, but it earns a place in the formula on its own merits. Combined with the two lactobacilli and the prebiotic-nutrient stack, it adds a layer of support that pure single-strain products miss.
Editorial note: Reviewed by Dr. Emily Carter, DDS. Last updated May 12, 2026. Citations linked inline. See our editorial policy.
